Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 5/20 | 0.57 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.57 |
| ▸ | FABP3 | P05413 | 2/20 | 0.50 |
| ▸ | FABP4 | P15090 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.41 |
| ▸ | BCL2 | P10415 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL212716 | 0.85 | FABP3 (0.60) | GABRA1GABRB2FABP3FABP4GAA | |
| SCHEMBL27897300 | 0.85 | GABRA1 (0.57) | GABRA1GABRB2FABP3FABP4GAA | |
| SCHEMBL29593831 | 0.85 | FABP3 (0.60) | GABRA1GABRB2FABP3FABP4GAA | |
| Water SCHEMBL5706121 | 0.83 | FABP3 (0.58) | GABRA1GABRB2FABP3FABP4GAA | |
| SCHEMBL6910525 | 0.83 | FABP3 (0.58) | GABRA1GABRB2FABP3FABP4GAA | |
| SCHEMBL11794494 | 0.83 | FABP3 (0.58) | GABRA1GABRB2FABP3FABP4GAA | |
| SCHEMBL10618114 | 0.83 | FABP3 (0.58) | GABRA1GABRB2FABP3FABP4GAA | |
| SCHEMBL11783529 | 0.83 | FABP3 (0.58) | GABRA1GABRB2FABP3FABP4GAA | |
| SCHEMBL11797932 | 0.83 | FABP3 (0.58) | GABRA1GABRB2FABP3FABP4GAA | |
| SCHEMBL5341709 | 0.83 | GABRA1 (0.55) | GABRA1GABRB2FABP3FABP4GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7208518-B2 | Substituted furochromene compounds of antiinflammatory action | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2007-04-24 | — | — | US | disclosed |
| US-20060148890-A1 | Substituted furochromene compounds of antiinflammatory action | PLIVA-LSTRAZIVACKI INSTITUT D.O.O. (HR) | 2006-07-06 | — | — | US | disclosed |
| EP-1648901-A1 | SUBSTITUTED FUROCHROMENE COMPOUNDS OF ANTIINFLAMMATORY ACTION | PLIVA-ISTRAZIVACKI INSTITUT d.o.o. (HR) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005010006-A1 | SUBSTITUTED FUROCHROMENE COMPOUNDS OF ANTIINFLAMMATORY ACTION | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-02-03 | — | — | WO | disclosed |
| US-20040019072-A1 | Dimer-selective RXR modulators and methods for their use | CANAN-KOCH STACIE (US) | 2004-01-29 | — | — | US | disclosed |
| EP-1336600-A2 | Dimer-selective RXR modulators and methods for their use | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2003-08-20 | — | — | EP | disclosed |
| US-6545049-B1 | E.g., (2E, 4E, 6E)-7-(3,5-diisopropyl-2-n-heptyloxyphenyl)-3-methylocta-2,4,6-trienoic acid, esters or amides thereof | LIGAND PHARMACEUTICALS INCORPORATED | 2003-04-08 | — | — | US | disclosed |
| EP-0873295-B1 | DIMER-SELECTIVE RXR MODULATORS AND METHODS FOR THEIR USE | LIGAND PHARM INC (US) | 2003-04-02 | — | — | EP | disclosed |
| EP-0873295-A1 | DIMER-SELECTIVE RXR MODULATORS AND METHODS FOR THEIR USE | LIGAND PHARMACEUTICALS, INC. (US) | 1998-10-28 | — | — | EP | disclosed |
| WO-1997012853-A1 | DIMER-SELECTIVE RXR MODULATORS AND METHODS FOR THEIR USE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019072-A1 | Dimer-selective RXR modulators and methods for their use | RXRG, RXRB, RXRA | GABRA1 67/4885GABRB2 70/4885FABP3 269/4885 |
| US-20060148890-A1 | Substituted furochromene compounds of antiinflammatory action | LTC4S, CYP11B2, CYP11B1 | GABRA1 3950/4885GABRB2 3680/4885FABP3 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.